Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

3 recruiting4 with results

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Early Phase 1

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05330182Phase 2Recruiting

LMN-201 for Prevention of C. Difficile Infection Recurrence

Role: lead

NCT04182490Phase 2Completed

LMN-101 in a Campylobacter Human Challenge Model

Role: lead

NCT06363890Recruiting

Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia

Role: lead

NCT06030414Phase 1Completed

A Study to Determine the Tolerability of Intranasal LMN-301

Role: lead

NCT04893239Phase 1Completed

Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies

Role: lead

NCT04098263Phase 1Completed

Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers

Role: lead

NCT06556940Early Phase 1Recruiting

G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies

Role: lead

All 7 trials loaded